Matthew Henn

Company: Seres Therapeutics

Job title: Chief Scientific Officer & Executive Vice President

Seminars:

Panel Discussion: Approval & Beyond: Future Perspectives for Microbiome Based Therapeutics 8:30 am

Real world evidence of healthcare professional adoption of microbiome-based therapeutics (FMT and LBPs) Pricing, reimbursement insurance coverage Exploring manufacturing and scale-up considerationsRead more

day: Conference Day One

Advances & Challenges in Realizing the Full Potential of Microbiome Therapeutic Interventions 9:30 am

Outlining the past year’s FDA approvals of microbiome therapeutics; the approvals are an important starting point Exploring what broad opportunity sets remains for utilizing microbiome-based technologies Realizing the potential for microbiome-based therapeutics demands additional technology advancements and navigating scientific, regulatory, and investment risksRead more

day: Conference Day One